Migraine Abortive Medication Zomig Now Generic

Teri Robert @trobert Health Guide
  • Generic versions of the Migraine abortive medication Zomig (zolmitriptan) — the oral tablets and orally disintegrating tablets (Zomig-ZMT) — have been approved by the FDA and are now shipping to pharmacies.

     

    Several manufacturers are now producing generic zolmitriptan:

    • Glenmark Generics is producing 2.5 and 5mg oral tablets and 2.5 and 5 orally disintegrating tablets.
    • Apotec, Inc. is producing 2.5 and 5mg oral tablets and 2.5 and 5 orally disintegrating tablets.
    • Mylan Generics is producing 2.5 and 5mg oral tablets.
    • Zydus Pharmaceuticals is producing 2.5 and 5mg orally disintegrating tablets.

    Teva Pharmaceuticals has received tentative approval for the 2.5 and 5mg oral tablets, but is not producing or shipping yet. The patent on Zomig Nasal Spray, which was approved by the FDA later than the tablets, has not yet expired, so zolmitriptan nasal spray is not yet available.

    Add This Infographic to Your Website or Blog With This Code:

     

    Zomig / zolmitriptan is one of the triptan medications, a Migraine abortive medication that works to stop the Migrainous process, actually stopping the Migraine attack and its symptoms rather than just temporarily masking the symptoms. You can read more about this type of medication in Preventive, Abortive, and Rescue Medications - What's the Difference?. Zolmitriptan is approved for the acute treatment of Migraine in adults.

     

    ____________

    Resources:

     

    Drugs@FDA. FDA Approved Drug Products.

    Live well,

     

     

     

    Get the latest Migraine and headache news, informational articles, tips for living well, and more in my free Putting Our Heads Together newsletter. To subscribe, CLICK HERE.


     

     

    Follow me on    or 


    BlogWithIntegrity.com

     

     

    Page copy protected against web site content infringement by Copyscape© Teri Robert, 2013.
    Last updated May 20, 2013.

Published On: May 20, 2013